Revolutionary IP is left sitting on the shelves at leading universities, Upwards of 95% of patented university innovations go unfunded and never reach commercial market.
Investors can now capitalize on exclusive opportunities related to the commercialization of disruptive intellectual property and startup companies.
The DiretoTech ecosystem is focused on disrupting every step of the $75 billion per year debt collection, notification, payment, credit and cashback market in Brazil.
Direto has developed proprietary technology linking Creditors, Public Notaries and Debtors at scale, replacing an antiquated, bureaucratic, in person system, with a fully digital infrastructure.
DiretoTech consolidates five portfolio companies in order to scale nationally in Brazil and is currently raising a growth funding round.
AssetWatch, formerly Nikola Labs, is the developer and provider of a rapidly deployable, end-to-end condition monitoring platform designed to prevent unplanned downtime. Unplanned downtime is a trillion dollar problem for global manufacturers. The company's wireless vibration and temperature sensors collect machine health data presented on cloud-based software and condition monitoring engineers and machine learning algorithms analyze data, providing predictive insight and enabling proactive maintenance before machines fail.
Having graduated from Ikove’s Startup Nursery, AssetWatch now proudly serves 160+ customers with systems installed in 410+ facilities.
Atreon’s mission is building a line of orthopedic products that provide a structure for improved healing of sports medicine injuries.
Rotium is an electrospun, bioresorbable synthetic scaffold placed at the tendon-to-bone interface created to address the inferior healing of existing solutions. Tendon-to-Bone injuries impact over 10 million people. Rotium is designed to promote tendon healing by regenerating native tissue architecture and strong tendon-bone integration by providing a healing environment that shortens the inflammatory stage, therefore restoring function and improving procedures' success rates.
Ikove has a unique venture development model. We primarily invest in companies that we co-found. We focus on technologies coming out of Universities and Research Institutions around the country. When the circumstances are appropriate, we will also co-found joint ventures with established companies or startups. These JV’s usually develop from opportunities to establish new industry verticals or to establish operations in new geographies.
Ikove pursues technologies that have been developed and reinforced by significant investments in R&D at leading research institutions. Technologies are vetted through our Startup Nursery, and if they successfully move through our pipeline process, we recruit CEOs and operators to be part of the founding cap table of the companies.
We are headquartered in the Midwest, where we have access to world-class technologies, infrastructure and teams at a fraction of the cost of the East and West Coasts. Our CEOs can relocate the companies where they see a strategic fit but still have the benefits of lower costs and valuation arbitrage as the operating businesses settles in places like San Francisco, New York City or Hong Kong.
Ikove is heavily involved in the launch and operations of the business alongside each company’s management team. This allows the founding team to focus on the product and their market. We focus on deep tech businesses, to focus on disrupting industries that are backed by strong and significant IP.
We invest in technologies that solves big problems with significant market potential and are backed by strong intellectual property and knowhow.
We build our companies to become fast-growing, profitable businesses that can go all the way to IPOs; but given current exit dynamics, we position our portfolio companies in a way that they can be acquisition targets. We develop our companies with a clear “build-to-sell” focus.
Through our proprietary Startup Nursery, in partnership with multiple U.S. research institutions, We identify and validate developing high-impact technologies, providing capital and commercialization resources to bridge the gap between R&D and VC funded rounds.